# VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

> **NCT01134484** · PHASE3 · UNKNOWN · sponsor: **Michele Cavo** · enrollment: 480 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Velcade
- **DRUG:** Thalidomide
- **DRUG:** Dexamethasone
- **PROCEDURE:** Peripheral Blood Stem Cell (PBSC) collection
- **PROCEDURE:** First Autologous Transplantation
- **PROCEDURE:** Second Autologous Transplantation

## Key facts

- **NCT ID:** NCT01134484
- **Lead sponsor:** Michele Cavo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-05
- **Primary completion:** 2008-08
- **Final completion:** 2015-12
- **Target enrollment:** 480 (ACTUAL)
- **Last updated:** 2012-07-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134484, "VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01134484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*